Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
142
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
stocks
Chart of the Week: Lithium is rebounding on rising demand
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.60 | 23.80 | -0.25% |
| CAC 40 | 8,374.03 | 55.00 | -0.65% |
| DAX 40 | 25,043.15 | 235.06 | -0.93% |
| Dow JONES (US) | 49,662.66 | 129.47 | 0.26% |
| FTSE 100 | 10,627.84 | 58.34 | -0.55% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,753.63 | 175.25 | 0.78% |
| Nikkei 225 | 57,467.83 | 323.99 | 0.57% |
| NZX 50 Index | 13,444.20 | 197.18 | 1.49% |
| S&P 500 | 6,881.31 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,086.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |